US 11,857,525 B2
Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
Jill Hamilton-Reeves, Shawnee, KS (US); Jeffrey M. Holzbeierlein, Mission Hills, KS (US); and Thomas Yankee, Overland Park, KS (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 15/548,186
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
PCT Filed Feb. 15, 2016, PCT No. PCT/EP2016/053156
§ 371(c)(1), (2) Date Aug. 2, 2017,
PCT Pub. No. WO2016/128576, PCT Pub. Date Aug. 18, 2016.
Claims priority of provisional application 62/116,155, filed on Feb. 13, 2015.
Prior Publication US 2018/0021279 A1, Jan. 25, 2018
Int. Cl. A61K 31/198 (2006.01); A61K 31/07 (2006.01); A61K 31/202 (2006.01); A61K 31/70 (2006.01); A23L 33/12 (2016.01); A23L 33/13 (2016.01); A23L 33/14 (2016.01); A23L 33/00 (2016.01); A23L 33/175 (2016.01); A23L 33/155 (2016.01); A61K 9/00 (2006.01); A61K 31/7088 (2006.01)
CPC A61K 31/198 (2013.01) [A23L 33/12 (2016.08); A23L 33/13 (2016.08); A23L 33/14 (2016.08); A23L 33/155 (2016.08); A23L 33/175 (2016.08); A23L 33/30 (2016.08); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 31/07 (2013.01); A61K 31/202 (2013.01); A61K 31/70 (2013.01); A61K 31/7088 (2013.01); A23V 2002/00 (2013.01)] 9 Claims
 
1. A method of treating or preventing cachexia induced by at least one of surgery, cancer or infection in a patient who is an individual with bladder cancer scheduled to undergo a radical cystoprostatectomy, the method comprising administering to the patient a specialized immunonutrition supplement comprising a combination of L-arginine, omega-3 fatty acids, vitamin A, and nucleotides, and
the specialized immunonutrition supplement is administered to the patient in a daily dose that provides an amount of the omega-3 fatty acids that comprises about 0.5 g to about 10.0 g of eicosapentaenoic acid and docosahexaenoic acid in total per day and that provides at least about 500 μg RE of the vitamin A per day; and
the specialized immunonutrition supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to the radical cystoprostatectomy to a post-operative day that is three to seven days after the radical cystoprostatectomy.